Skip to content

Author

M. Filzmayer

We have 3 of 43 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Cancer‐Control Outcomes of Japanese Vs. German Metastatic Hormone‐Sensitive Prostate Cancer Patients: A Real‐World Cross‐Country Comparison of Patients Undergoing Combination Therapies

Differences in tumor biology, ethnicities, and healthcare structures across populations may contribute to variability in oncologic outcomes. This study compared baseline characteristics and oncologic outcomes of Japanese and German metastatic hormone‐sensitive prostate cancer (mHSPC) patients.

Mike Wenzel, Keiichiro Miyajima, M. Filzmayer et al. · 1 citation
Aug 2026

Cancer-specific mortality in high-risk or very high-risk prostate cancer patients treated with focal therapy vs. radical prostatectomy.

INTRODUCTION Focal therapy (FT) in high-risk or very high-risk prostate cancer (CaP) is not guideline-recommended. However, it may be occasionally used, but its effect on cancer-specific mortality (CSM) relative to standard treatment options such as radical prostatectomy (RP) is unknown and was addressed in the present...

L. Quarta, M. Petix, M. Filzmayer et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.